• news.cision.com/
  • CLS/
  • CLS reschedules the publication of the Q3 2024 interim report to an earlier date and invites to a webcast
English

CLS reschedules the publication of the Q3 2024 interim report to an earlier date and invites to a webcast

Report this content

Lund, Sweden – Clinical Laserthermia Systems AB (publ) ("CLS" or “the Company") today announces that the Company is bringing forward the publication of its interim report for the third quarter 2024. The new date for publication is Thursday 31 October 2024. The previously announced date was Friday, November 15, 2024.

The reason for bringing forward the interim report to an earlier date is linked to the redemption of warrants of series TO 7 B that will take place during the month of November.

In connection with the publication of the report, CLS invites investors, analysts and media to a webcast on October 31 at 10:00-10:40 (CET). The company's CEO, Dan Mogren and CFO, Håkan Rosqvist will then present CLS and comment on the report. The presentation will be followed by a Q&A session where participants will be given the opportunity to ask questions via the webcast's video chat.

If you wish to participate via the webcast, please visit the following link: Live Q: Clinical Laserthermia Systems - Redeye

The webcast can also be viewed afterwards via CLS's website: www.clinicallaser.se

 

For more information, please contact:


Dan J. Mogren, CEO, Clinical Laserthermia Systems AB (publ)

Tel: +46 – (0)705 – 90 11 40


E-mail: dan.mogren@clinicallaser.com

 

 

About CLS

Clinical Laserthermia Systems AB (publ), develops and sells TRANBERG®|Thermal Therapy System and ClearPoint Prism Neuro Laser Therapy System with sterile disposables, for minimally invasive treatment of cancer tumors and drug-resistant epilepsy. The products are marketed and sold directly or through partners for image-guided laser ablation and are used in studies for treatment with imILT®, the company's interstitial laser thermotherapy for immune stimulating ablation with potential abscopal treatment effect. CLS is headquartered in Lund, Sweden, with subsidiaries in Germany, the United States and a marketing company in Singapore. CLS is listed on Nasdaq First North Growth Market under the symbol CLS B. Certified adviser (CA) is FNCA Sweden AB.

 

For more information about CLS, please visit the Company's website: www.clinicallaser.se

 

Subscribe

Documents & Links